EA200701841A1 - Новые фармацевтические композиции для лечения тромбоза - Google Patents

Новые фармацевтические композиции для лечения тромбоза

Info

Publication number
EA200701841A1
EA200701841A1 EA200701841A EA200701841A EA200701841A1 EA 200701841 A1 EA200701841 A1 EA 200701841A1 EA 200701841 A EA200701841 A EA 200701841A EA 200701841 A EA200701841 A EA 200701841A EA 200701841 A1 EA200701841 A1 EA 200701841A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical compositions
inhibitors
new pharmaceutical
antagonists
factor
Prior art date
Application number
EA200701841A
Other languages
English (en)
Other versions
EA015122B1 (ru
Inventor
Пол А. Рейлли
Джеймс С. Джилберт
Томас Х. Мюллер
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36423564&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200701841(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA200701841A1 publication Critical patent/EA200701841A1/ru
Publication of EA015122B1 publication Critical patent/EA015122B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В заявке описаны новые фармацевтические композиции, включающие по меньшей мере один прямой ингибитор тромбина и по меньшей мере одно дополнительное активное соединение, выбранные из группы, включающей ингибиторы агрегации тромбоцитов, обладающие низкой молекулярной массой гепарины (НММГ) и гепариноиды, а также нефракционированный гепарин, ингибиторы фактора Х, объединенные ингибиторы тромбина/фактора Х, антагонисты фибриногенового рецептора (антагонисты гликопротеина IIb/IIa) и антагонисты витамина Кнеобязательно с одним или большим количеством фармацевтически приемлемых инертных наполнителей или носителей, предназначенные для лечения тромбоза.
EA200701841A 2005-03-29 2006-03-27 Фармацевтическая композиция и ее применение для лечения тромбоза EA015122B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05006711 2005-03-29
PCT/EP2006/061046 WO2006103206A2 (en) 2005-03-29 2006-03-27 Combinations comprising at least one direct thrombin inhibitor for the treatment of thrombosis

Publications (2)

Publication Number Publication Date
EA200701841A1 true EA200701841A1 (ru) 2008-02-28
EA015122B1 EA015122B1 (ru) 2011-06-30

Family

ID=36423564

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701841A EA015122B1 (ru) 2005-03-29 2006-03-27 Фармацевтическая композиция и ее применение для лечения тромбоза

Country Status (19)

Country Link
US (2) US20060222640A1 (ru)
EP (1) EP1885354A2 (ru)
JP (1) JP2008534552A (ru)
KR (1) KR20070116936A (ru)
CN (1) CN101151030A (ru)
AR (1) AR056291A1 (ru)
AU (1) AU2006228600A1 (ru)
BR (1) BRPI0608656A2 (ru)
CA (1) CA2602563A1 (ru)
CL (1) CL2010000395A1 (ru)
EA (1) EA015122B1 (ru)
IL (1) IL186267A0 (ru)
MX (1) MX2007010664A (ru)
NO (1) NO20074149L (ru)
NZ (1) NZ562775A (ru)
TW (1) TW200722089A (ru)
UA (1) UA92603C2 (ru)
WO (1) WO2006103206A2 (ru)
ZA (1) ZA200706698B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906894B1 (en) 2000-07-27 2014-12-09 Thomas N. Thomas Methods for preventing and treating thrombotic disorders
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
IL159273A0 (en) * 2003-12-09 2004-06-01 Transpharma Medical Ltd Transdermal delivery system for sustained release of polypeptides
WO2006131931A2 (en) * 2005-06-10 2006-12-14 Transpharma Medical, Ltd. Patch for transdermal drug delivery
AR062057A1 (es) * 2006-07-17 2008-10-15 Boehringer Ingelheim Int Uso de los inhibidores directos de la trombina
CA2666396A1 (en) * 2006-10-10 2008-04-17 Boehringer Ingelheim International Gmbh Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
DE102006051625A1 (de) 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
JP5508272B2 (ja) * 2007-10-29 2014-05-28 トランスファーマ メディカル リミテッド 垂直的なパッチ乾燥
WO2010013231A2 (en) * 2008-07-29 2010-02-04 Yeda Research And Development Co. Ltd. Modulation of coagulation factors and effectors of same for control of transplant organ size
WO2010029552A1 (en) * 2008-09-10 2010-03-18 Transpharma Medical Ltd. Transdermal delivery of oligosaccharides
BRPI0921479A2 (pt) * 2008-11-11 2016-01-12 Boehringer Ingelheim Int método para tratamento ou prevenção de trombose usando etexilato de dabigatran ou um sal do mesmo com aprimorado perfil de segurança em relação à terapia convencional com varfarina
CN102209546A (zh) * 2008-11-11 2011-10-05 贝林格尔.英格海姆国际有限公司 使用达比加群酯或其盐治疗或预防血栓形成且与常规的华法林疗法相比具有改良有效性的方法
WO2010055023A1 (en) * 2008-11-11 2010-05-20 Boehringer Ingelheim International Gmbh Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
RU2011132125A (ru) 2008-12-30 2013-02-10 Тромбологик Апс Способы идентификации критических пациентов с повышенным риском развития органной недостаточности и соединения для их лечения
EP2667878B1 (en) * 2011-01-25 2016-03-30 Université Catholique de Louvain Compositions and methods for cell transplantation
CN102250099B (zh) * 2011-05-16 2013-10-16 中国药科大学 一类非肽类抗凝血酶抑制剂、其制法以及医药用途
US9775890B2 (en) 2012-01-25 2017-10-03 Université Catholique de Louvain Factor Xa inhibitor used with liver-derived progenitor cells
US20130345262A1 (en) 2012-06-25 2013-12-26 Boehringer Ingelheim International Gmbh Method for prevention of stroke
EP2722033A1 (en) * 2012-10-19 2014-04-23 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical Compositions of Dabigatran Free Base
WO2014060561A1 (en) * 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral pharmaceutical formulations comprising dabigatran
WO2015001124A1 (en) 2013-07-05 2015-01-08 Université Catholique de Louvain Conditioned medium from human adult liver stem cells and its use in the treatment of liver disorders
DE102014108210A1 (de) * 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105250286A (zh) * 2015-11-13 2016-01-20 谭惠娟 一种抗血栓组合物
CN108236612A (zh) * 2016-12-27 2018-07-03 李志忠 用于冠脉介入手术中抗凝的组合产品及其用途
WO2020180489A1 (en) * 2019-03-06 2020-09-10 University Of Rochester Anticoagulant compositions and uses thereof
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) * 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
NZ286082A (en) * 1995-03-15 1998-09-24 Behringwerke Ag Method of treating acute myocardial infarction with hirudin and acetylsalicylic acid in patients not undergoing thrombolytic treatment
FR2744918B1 (fr) * 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
US6414008B1 (en) * 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
DE19834751A1 (de) * 1998-08-01 2000-02-03 Boehringer Ingelheim Pharma Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
GB9930540D0 (en) * 1999-12-23 2000-02-16 Rhone Poulenc Rorer Pharma Chemical compounds
GB0014134D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
CA2460141C (en) * 2001-09-14 2012-01-10 Mitsubishi Pharma Corporation Drugs comprising combination of antithrombotic agent with pyrazolone derivative
CA2476054C (en) * 2002-03-07 2011-11-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical composition for the oral administration of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino)-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino)-propionic acid ethyl ester and the salts thereof
DE10235639A1 (de) * 2002-08-02 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel
CA2523157A1 (en) * 2003-04-24 2004-11-04 Boehringer Ingelheim International Gmbh Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression ofthrombin receptors

Also Published As

Publication number Publication date
AR056291A1 (es) 2007-10-03
EP1885354A2 (en) 2008-02-13
CN101151030A (zh) 2008-03-26
KR20070116936A (ko) 2007-12-11
WO2006103206A2 (en) 2006-10-05
IL186267A0 (en) 2008-01-20
JP2008534552A (ja) 2008-08-28
EA015122B1 (ru) 2011-06-30
BRPI0608656A2 (pt) 2010-01-19
UA92603C2 (ru) 2010-11-25
US20060222640A1 (en) 2006-10-05
MX2007010664A (es) 2007-12-12
CL2010000395A1 (es) 2010-08-20
WO2006103206A3 (en) 2007-01-11
TW200722089A (en) 2007-06-16
US20100184729A1 (en) 2010-07-22
CA2602563A1 (en) 2006-10-05
AU2006228600A1 (en) 2006-10-05
NZ562775A (en) 2011-03-31
ZA200706698B (en) 2008-12-31
NO20074149L (no) 2007-12-11

Similar Documents

Publication Publication Date Title
EA200701841A1 (ru) Новые фармацевтические композиции для лечения тромбоза
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
BRPI0415449A (pt) combinações de compostos ativos fungicidas sinergìsticos
CO5580771A2 (es) Antagonistas ccr5 como agentes terapeuticos
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
HRP20080564T3 (en) Dihydrotetrabenazines and pharmaceutical compositions containing them
CY1111212T1 (el) Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ
SE0302760D0 (sv) New compounds
AR043795A1 (es) Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c
WO2008065500A3 (en) Heteroaryl amides as type i glycine transport inhibitors
RS52874B (en) THYOPHEN ANALYSIS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
DE602004016831D1 (de) Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
ATE478867T1 (de) Substituierte quinazolinone verbindungen
EA201100795A1 (ru) Фармацевтическая композиция эффективного ингибитора всг для перорального введения
DE60324544D1 (de) Muskarin antagonisten
EA200870545A1 (ru) Новые гетероциклические соединения
NO20063393L (no) Farmasoytiske preparater
BRPI0713132B8 (pt) compostos derivados de cinamoil-piperazina, método de preparação dos referidos compostos, composições farmacêuticas, seus usos como antagonistas de par-i e produtos
EA201000329A1 (ru) Циклические депсипептиды
ATE225349T1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
BRPI0608184A2 (pt) composições farmacêuticas compreendendo inibidores da nep, inibidores da nep, inibidores do sistema de produção de endotelina endógena e diuréticos
AR057885A1 (es) Acido 1-(1-(2- etoxietil) - 1- etil-7-(4- metilpiridin -2- ilamino)- 1h pirazolo (4,3-d) pirimidin -5- il) piperidina -4- carboxilico y las sales del mismo. composiciones farmaceuticas.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU